Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL

Overview of attention for article published in Nature Genetics, February 1998

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

patent: 44 patents

Readers on

mendeley: 68 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 44 patents that reference this research output.

AN EZH2 DEGRADER OR INHIBITOR FOR USE IN THE TREATMENT OF RESISTANT ACUTE MYELOID LEUKEMIA

Application WO-2023111173-A1

World Intellectual Property Organisation (WIPO)

22 Jun 2023

Histone deacetylase inhibitors

Grant US-10172821-B2

United States of America

08 Jan 2019

Treatment of protein degradation disorders

Grant US-10172905-B1

United States of America

08 Jan 2019

Class-and isoform-specific HDAC inhibitors and uses thereof

Grant US-10059657-B2

United States of America

28 Aug 2018

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 40 additional patents.